Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ)’s share price fell 1.4% during mid-day trading on Thursday . The stock traded as low as $3.44 and last traded at $3.50, with a volume of 157,885 shares trading hands. The stock had previously closed at $3.55.

The stock’s 50-day moving average is $3.61 and its 200-day moving average is $4.65. The company’s market cap is $228.55 million.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last announced its quarterly earnings results on Tuesday, May 10th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.25) by $0.48. The business earned $8.10 million during the quarter, compared to the consensus estimate of $9.70 million. Aralez Pharmaceuticals’s quarterly revenue was up 84.1% compared to the same quarter last year. On average, equities analysts forecast that Aralez Pharmaceuticals Inc. will post ($1.00) earnings per share for the current fiscal year.

In other Aralez Pharmaceuticals news, insider James Patrick Tursi acquired 10,000 shares of the business’s stock in a transaction dated Friday, May 20th. The stock was acquired at an average cost of $3.75 per share, for a total transaction of $37,500.00. Following the completion of the transaction, the insider now directly owns 179,368 shares of the company’s stock, valued at $672,630. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Andrew I. Koven acquired 71,500 shares of the business’s stock in a transaction dated Thursday, May 12th. The stock was acquired at an average price of $3.49 per share, with a total value of $249,535.00. Following the completion of the transaction, the insider now directly owns 1,610,306 shares of the company’s stock, valued at $5,619,967.94. The disclosure for this purchase can be found here.

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.